A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours

Published 2017 View Full Article

  1. Home
  2. Publications
  3. Publication Search
  4. Publication Details
Title
A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours
Authors
Keywords
De-differentiated liposarcoma, HDM2, MDM2, p53, Pharmacokinetics, Pharmacodynamics, SAR405838, Solid tumours
Journal
EUROPEAN JOURNAL OF CANCER
Volume 76, Issue -, Pages 144-151
Publisher
Elsevier BV
Online
2017-03-17
DOI
10.1016/j.ejca.2017.02.005

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now
Webinars Posters Questions Hubs Funding Journals Articles Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.